Navigation Links
Lilly announces Tapiero retiring; Zulueta promoted to senior vice president and president of Emerging Markets
Date:10/24/2013

INDIANAPOLIS, Oct. 24, 2013 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that Alfonso "Chito" Zulueta will be promoted to senior vice president and president of the Emerging Markets business effective Jan. 1, 2014. Zulueta will replace Jacques Tapiero who will retire Jan. 31, 2014, after 31 years of service to the company.

Zulueta has been president and general manager of Lilly Japan since 2008. In his new role, he will lead the company's efforts in many of the world's fastest-growing markets in Asia, Latin America, Middle East and Africa, plus Russia and Turkey.  Zulueta will report to John Lechleiter, Ph.D., chairman, president, and CEO, and will serve on the company's executive committee.

Tapiero joined Lilly in 1983 as a financial analyst. He became president of Emerging Markets in 2009. Prior to that, he had served as president of the intercontinental region for Lilly, which comprised offices in Asia, Australia, Africa, the Middle East, Canada, Latin America, and Russia, and had been general manager of several affiliates.

"Jacques Tapiero has made extraordinary contributions to our company throughout his 31-year career with Lilly, culminating in 2009 with his appointment to lead our important Emerging Markets business," Lechleiter said. "Jacques' leadership has been characterized by strong operational skills and a keen focus on the development of Lilly people around th
'/>"/>

SOURCE Eli Lilly and Company
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Lilly Reports Third-Quarter 2013 Results
2. FDA Grants Lillys Ramucirumab Priority Review as a Potential Single-Agent Treatment for Advanced Gastric Cancer
3. Lilly Declares Fourth-Quarter 2013 Dividend
4. Lilly Reintegration Scholarship Applications Available for 2014-2015 Academic Year
5. Lilly to host investment community meeting at its Indianapolis headquarters on Thursday, October 3, 2013
6. Data Presented at 49th EASD Annual Meeting Show Treatment with Lillys Investigational Dulaglutide Resulted in Improved Patient-Reported Health Outcomes
7. Lilly Announces Second Positive Ramucirumab Phase III Gastric Cancer Study Meets Primary Endpoint; Phase III Lilly/TRIO Breast Cancer Study Misses Primary Endpoint
8. Exosome Diagnostics Enters Collaboration Agreement with Lilly for Exosome Blood-Based Biomarker Discovery
9. Lilly to Present Data Across its Diabetes Portfolio at the 49th European Association for the Study of Diabetes Annual Meeting
10. Humana and Lilly Form Research Collaboration to Improve Health Care Outcomes
11. Dr. Marschall S. Runge Elected to Lilly Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... Revenue and earnings above the previous year - ... In the past 2013/14 fiscal year (ended 30 September ... 4.287 billion (last year: EUR 4.190 billion) despite unfavorable currency ... million. "Overall, 2013/14 was a successful fiscal year for the ... CEO of Carl Zeiss AG. "Thanks to our broad portfolio ...
(Date:12/17/2014)... , Dec. 17, 2014 With ... (MRI), the MRI market is seeing new growth, ... breast MRI scans account for the majority of ... higher resolution of images, which are creating opportunities for ... (MRI) market is growing at a rate of ...
(Date:12/17/2014)... 17, 2014  ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular") (NYSE ... Trademark Office (USPTO) has issued a key patent ... immunotherapeutic vaccine targeting six tumor antigens that are ... Patent No. 8,871,211, which issued October 28, 2014, ... a dendritic cell composition comprising peptide epitopes of ...
Breaking Medicine Technology:ZEISS Asserts its Position in Difficult Environment 2Kalorama: 3T Advancements Bringing New Growth to the MRI Market 2Kalorama: 3T Advancements Bringing New Growth to the MRI Market 3ImmunoCellular Therapeutics Announces Issuance of Key Patent For ICT-107 Cancer Vaccine 2
... 2011 Actavis Group, the international generic pharmaceuticals company, today ... a binding letter of intent (LOI) with QRxPharma Limited (ASX: ... United States.  Under the terms of the ... IR, a patented 3:2 ratio fixed dose combination of morphine ...
...  QRxPharma Limited (ASX: QRX and OTCQX: QRXPY) announced today execution ... for the formation of a strategic partnership to commercialise MoxDuo ... IR is a patented 3:2 ratio fixed dose combination of ... Group, hf a privately held company based in Europe with ...
Cached Medicine Technology:Actavis to Launch Novel Pain Medication in the US 2Actavis to Launch Novel Pain Medication in the US 3QRxPharma Announces Strategic Partnership with Actavis 2QRxPharma Announces Strategic Partnership with Actavis 3QRxPharma Announces Strategic Partnership with Actavis 4QRxPharma Announces Strategic Partnership with Actavis 5
(Date:12/21/2014)... Columbus, OH (PRWEB) December 21, 2014 ... of men alleging heart attacks, stroke and blood clots ... continue to increase, a new study shows that the ... developing colon cancer. In a study published in the ... lead researcher, James Amos-Landgraf examined a group of male ...
(Date:12/20/2014)... 2014 BambooIndustry.com is a professional company ... The business has recently shown its new engineered bamboo ... its bamboo flooring models. , BambooIndustry.com’s customers come from ... and more. According to the CEO of the company, ... fast in the past few years, and the demand ...
(Date:12/20/2014)... 20, 2014 An improving macroeconomic landscape ... benefited the Massage Services industry over the ... industry products, the anticipated 1.0% annualized increase in per ... consumers with the means to afford additional massages. “While ... massage in a given year has declined from 2009 ...
(Date:12/20/2014)... Dec. 20, 2014 (HealthDay News) -- The holidays can ... they contend with fresh trees, scented candles and other ... on the decorations that have been packed away in ... my allergy and asthma patients," Dr. Rachna Shah, an ... of Medicine, said in Loyola news release. Shah, ...
(Date:12/20/2014)... December 20, 2014 As Risperdal ... forward in U.S. courts, Bernstein Liebhard LLP notes ... that children treated with the medication may experience ... breast development and lactation. The study, which appears ... and adolescents who began treatment with risperidone, an ...
Breaking Medicine News(10 mins):Health News:New Low Testosterone Therapy Study Shows Male Hormone Testosterone May Contribute To Colon Cancer Reports Wright & Schulte LLC 2Health News:New Low Testosterone Therapy Study Shows Male Hormone Testosterone May Contribute To Colon Cancer Reports Wright & Schulte LLC 3Health News:New Low Testosterone Therapy Study Shows Male Hormone Testosterone May Contribute To Colon Cancer Reports Wright & Schulte LLC 4Health News:BammbooIndustry.com: Big Discounts On All Kinds Of Bamboo Flooring Collections 2Health News:Massage Services in the US Industry Market Research Report from IBISWorld Has Been Updated 2Health News:Massage Services in the US Industry Market Research Report from IBISWorld Has Been Updated 3Health News:Holiday Trimmings Can Trigger Allergies 2Health News:Risperdal Lawsuit News: Bernstein Liebhard LLP Notes Publication of Study Suggesting Medication May Raise Prolactin Levels in Children 2Health News:Risperdal Lawsuit News: Bernstein Liebhard LLP Notes Publication of Study Suggesting Medication May Raise Prolactin Levels in Children 3Health News:Risperdal Lawsuit News: Bernstein Liebhard LLP Notes Publication of Study Suggesting Medication May Raise Prolactin Levels in Children 4
... studies published in the United States have determined that young ... to smoke. To combat smoking among youth, public health ... depict smoking. A new study from New Zealand, however, ... may not have the intended effect of putting such movies ...
... for Testing by End of School ... ... Education Agency,(TEA) announced today it has selected FITNESSGRAM(R), created by The Cooper,Institute ... annual testing of more than four million Texas,3rd through 12th grade students ...
... E. coli O157:H7 vaccine named "best new veterinary product for livestock" ... ... -, BELLEVILLE, ON, Sept. 27 /PRNewswire-FirstCall/ - Bioniche Life,Sciences ... its vaccine against E. coli,O157:H7 in cattle has been recognized internationally ...
... Product, ABBOTT PARK, Ill., Sept. 27 ... autoimmune diseases, has received the,2007 Galen Prize for ... approved fully human antibody. HUMIRA is approved,for use ... arthritis,psoriatic arthritis, ankylosing spondylitis and moderate to severe ...
... Climb to Conquer Cancer will follow four professional U.S., ... Alaska, NEW YORK, Sept. 27 Fred Hutchinson ... expedition to an unclimbed,mountain in the name of cancer ... expedition. The inaugural Climb to Conquer Cancer, performed ...
... lower their quality of life, survey finds , ... with diabetes, the burden of adhering to their daily ... complications, a U.S. study finds. , University of Chicago ... type 2 diabetes. , As reported in the October ...
Cached Medicine News:Health News:R rating might be unlikely to affect teens exposure to smoking in movies 2Health News:The Cooper Institute's FITNESSGRAM Selected as Statewide Physical Fitness Assessment Tool 2Health News:The Cooper Institute's FITNESSGRAM Selected as Statewide Physical Fitness Assessment Tool 3Health News:The Cooper Institute's FITNESSGRAM Selected as Statewide Physical Fitness Assessment Tool 4Health News:Bioniche Food Safety Vaccine Receives Global Top Honours in Industry Excellence Awards 2Health News:Bioniche Food Safety Vaccine Receives Global Top Honours in Industry Excellence Awards 3Health News:Bioniche Food Safety Vaccine Receives Global Top Honours in Industry Excellence Awards 4Health News:Abbott's HUMIRA(R) (adalimumab) Honored With Prestigious Galen Prize for Innovation in Patient Care 2Health News:Abbott's HUMIRA(R) (adalimumab) Honored With Prestigious Galen Prize for Innovation in Patient Care 3Health News:Abbott's HUMIRA(R) (adalimumab) Honored With Prestigious Galen Prize for Innovation in Patient Care 4Health News:Abbott's HUMIRA(R) (adalimumab) Honored With Prestigious Galen Prize for Innovation in Patient Care 5Health News:Fred Hutchinson Cancer Research Center Announces the First-Ever Expedition to an Unclimbed Mountain in the Name of Cancer Research 2Health News:For Some, Diabetes Care Worse Than Illness Itself 2
0.2 mm hook with curved shaft to reach over lens optic. Flat serrated handle with polished finish. Overall length: 4.8 inches. Most popular size or model....
0.2 mm, 90o angled tip with curved 9 mm shaft. Flat smooth handle with polished finish. Overall length: 4.5 inches....
Angled 45 degrees, 10 mm shaft with 0.2 mm tip. Round knurled handle with dull finish. Overall length: 4.6 inches....
2.0 mm cup. Angled 45 degree shaft 8 mm from tip to bend with flat handle and polished finish. Overall length: 4.8 inches....
Medicine Products: